Molecular Profile Detail

Profile Name ERBB2 positive
Gene Variant Detail

ERBB2 positive (unknown)

Relevant Treatment Approaches HER inhibitor (Pan) HER2 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 positive Her2-receptor positive breast cancer sensitive trastuzumab emtansine Phase III Actionable In a Phase III trial, Kadclya (trastuzumab emtansine) demonstrated improved median progression free survival and overall survival compared to Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment in patients with ERBB2 (HER2) positive breast cancer, regardless of the expression level of Erbb2 (Her2), Egfr, and Her3, or PIK3CA mutation status (PMID: 26920887). 26920887
ERBB2 positive Her2-receptor positive breast cancer sensitive trastuzumab emtansine FDA approved Actionable In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166). 23020162 24879797
ERBB2 positive breast carcinoma sensitive SYD985 Preclinical - Pdx & cell culture Actionable In a preclinical study, SYD985 decreased survival of ERBB2 (HER2)-positive breast carcinoma cell lines in culture, and inhibited tumor growth and induced tumor remission in cell line and patient-derived xenograft models of ERBB2 (HER2)-positive breast carcinoma, including models with low ERBB2 (HER2) expression (PMID: 25589493). 25589493
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive ABP 980 Phase III Actionable In a Phase III trial, ABP 980 treatment demonstrated safety and efficacy similar to Herceptin (trastuzumab), with pathologic complete response rates of 48% and 40.5%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 151PD; NCT01901146). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Entinostat + Lapatinib Phase I Actionable In a Phase I trial, Entinostat and Tykerb (lapatinib) combination treatment resulted in complete response in 7% (1/15) and stable disease in 27% (4/15) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)). detail...
ERBB2 positive stomach cancer sensitive Lapatinib + Paclitaxel Phase III Actionable In a Phase III trial, second-line treatment using Tykerb (lapatinib) with paclitaxel demonstrated some efficacy in patients with HER2-positive advanced gastric cancer (PMID: 24868024). 24868024
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Lapatinib Clinical Study Actionable In a meta-analysis of six randomized clinical trials, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in 13% absolute improvement in pathologic complete response rate in ERBB2 (HER2)-positive breast cancer patients compared to Herceptin (trastuzumab) single treatment (PMID: 27140927). 27140927
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Lapatinib Phase II Actionable In a Phase II trial, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in complete response in the breast in 10.6% (7/66) and minimal residual disease in 16.7% (11/66) of ERBB2-positive breast cancer patients 11 days after receiving the treatment (European Breast Cancer Conference; Mar 2016; Abstract #6LBA). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Entinostat + Lapatinib + Trastuzumab Phase I Actionable In a Phase I trial, combination treatment consisted of Entinostat, Tykerb (lapatinib) and Herceptin (trastuzumab) resulted in complete response in 9% (2/22), partial response in 14% (3/22), and stable disease in 27% (6/22) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)). detail...
ERBB2 positive stomach carcinoma sensitive SYD985 Preclinical - Cell culture Actionable In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture (PMID: 25589493). 25589493
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Docetaxel + Carboplatin Guideline Actionable Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) therapy is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org). detail...
ERBB2 positive uterine corpus serous adenocarcinoma sensitive SYD985 Preclinical - Cell line xenograft Actionable In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-expressing primary uterine serous carcinoma (USC) cell lines in culture, including cell lines with both high and low levels of ERBB2 (HER2) expression, and inhibited tumor growth and improved survival in ERBB2 (HER2)-expressing USC primary cell line xenografts (PMID: 27256376). 27256376
ERBB2 positive Advanced Solid Tumor predicted - sensitive HER2 Inhibitor S-222611 Phase I Actionable In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923). detail... 25434923
ERBB2 positive stomach cancer sensitive HER2 Vaccine Preclinical - Patient cell culture Actionable In a preclinical study, ERBB2 (HER2)-specific cytotoxic T-cell lines generated from gastric cancer patients demonstrated activity against autologous ERBB2 (HER2)-expressing gastric cancer cells in culture (PMID: 9754653). 9754653
ERBB2 positive salivary gland cancer predicted - sensitive DS-8201a Phase I Actionable In a Phase I trial, treatment with DS-8201a resulted in a partial response in 50% (2/4) of evaluable patients with salivary gland cancer and ERBB2 (HER2) expression (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 409P; NCT02564900). detail...
ERBB2 positive breast cancer sensitive ADCT-502 Preclinical - Pdx Actionable In a preclinical study, ADCT-502 demonstrated anti-tumor activity in ERBB2 (HER2)-expressing breast cancer cell line and patient-derived xenograft (PDX) models, including PDX models expressing low levels of ERBB2 (HER2) (Eur J Cancer, 2016, Vol. 69, Supp1, S28). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Docetaxel + T-DM1 Phase Ib/II Actionable In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine) and Taxotere (docetaxel) combination treatment resulted in median progression-free survival of 13.8 months and objective response in 80.0% (20/25) of patients with ERBB2 (HER2)-positive metastatic breast cancer (PMID: 27052654). 27052654
ERBB2 positive pancreatic cancer sensitive DS-8201a Preclinical - Cell line xenograft Actionable In a preclinical study, DS-8201a inhibited tumor growth in a pancreatic cancer cell line xenograft model with low ERBB2 (HER2) expression (PMID: 27026201). 27026201
ERBB2 positive stomach cancer predicted - sensitive ZW25 Phase I Actionable In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123). detail...
ERBB2 positive breast cancer sensitive MI130004 Preclinical - Cell line xenograft Actionable In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-receptor positive breast cancer cells in culture, and led to decreased tumor volume and improved survival in cell line xenograft models (PMID: 29440297). 29440297
ERBB2 positive Her2-receptor positive breast cancer sensitive Hertuzumab-vc-MMAE Preclinical - Cell culture Actionable In a preclinical study, Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 27509865). 27509865
ERBB2 positive breast cancer sensitive HER2 Inhibitor Tucatinib + Trastuzumab emtansine Phase Ib/II Actionable In a Phase Ib/II trial, ERBB2 (HER2)-positive breast cancer patients demonstrated an objective response rate of 47% (16/34), including one complete response and fifteen partial responses, and a progression-free survival of 8.2 months when treated with a combination of Tucatinib (ARRY-380) and Kadcyla (trastuzumab emtansine) compared to 6.5 months with Herceptin (trastuzumab) and Perjeta (pertuzumab) treatment (PMID: 29955792; NCT01983501). 29955792
ERBB2 positive Her2-receptor positive breast cancer sensitive Sunitinib + Trastuzumab Phase II Actionable In a Phase II trial, Sutent (sunitinib), in combination with Herceptin (trastuzumab), demonstrated safety and efficacy in ERBB2 (HER2) positive advanced breast cancer patients (PMID: 24606768). 24606768
ERBB2 positive breast adenocarcinoma sensitive DS-8201a Preclinical - Cell culture Actionable In a preclinical study, DS-8201 inhibited growth of an ERBB2 (HER2)-positive breast adenocarcinoma cell line in culture (PMID: 27026201). 27026201
ERBB2 positive Her2-receptor positive breast cancer sensitive MM-302 Phase I Actionable In a Phase I study, MM-302 demonstrated safety in patients with ERBB2 (HER2) positive breast cancer (Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-09) detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive BKM120 + Trastuzumab Phase I Actionable In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated in patients with ERBB2 (HER2)-positive advanced or metastatic breast cancer that had progressed on Herceptin (trastuzumab) (PMID: 24470511). 24470511
ERBB2 positive Her2-receptor positive breast cancer sensitive HER2 Inhibitor Pyrotinib Phase I Actionable In a Phase I trial, Pyrotinib treatment resulted in an objective response rate of 50% (18/36, all partial responses), and a clinical benefit rate of 61.1% (22/36), and a median progression-free survival of 35.4 weeks in patients with ERBB2 (HER2)-positive breast cancer (PMID: 28498781, NCT01937689). detail... 28498781
ERBB2 positive stomach cancer sensitive Trastuzumab + Oxaliplatin Preclinical Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive gastric cancer cells in culture (PMID: 24300914). 24300914
ERBB2 positive Her2-receptor positive breast cancer sensitive HER2 Inhibitor Neratinib Phase II Actionable In a Phase II clinical trial, Nerlynx (neratinib) demonstrated safety and efficacy as a monotherapy in patients with ERBB2 (HER2)-positive breast cancer (PMID: 23953056). 23953056
ERBB2 positive Her2-receptor positive breast cancer sensitive HER2 Inhibitor Neratinib FDA approved Actionable In a Phase III trial that supported FDA approval, ERBB2 (HER2)-positive breast cancer patients previously treated with Herceptin (trastuzumab) demonstrated a significantly greater two year invasive disease-free survival rate (93.9%) when treated with Nerlynx (neratinib) compared to the rate (91.6%) in those patients treated with placebo (PMID: 26874901; NCT00878709). 26874901
ERBB2 positive Her2-receptor positive breast cancer sensitive Pertuzumab + Trastuzumab + Carboplatin + Docetaxel Guideline Actionable Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab) therapy, is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive MYL-1401O + Paclitaxel Phase III Actionable In a Phase III trial, MYL-1401O demonstrated safety and efficacy comparable to Herceptin (trastuzumab) when given in combination with Taxol (paclitaxel), resulted in an objective response rate of 69.6% in ERBB2 (HER2)-positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr LBA503)). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive MGAH22 Phase I Actionable In a Phase I trial, Margetuximab (MGAH22) treatment resulted in tumor reduction in 78% (18/23) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 28119295). 28119295
ERBB2 positive Her2-receptor positive breast cancer sensitive Copanlisib Preclinical Actionable In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2)-over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767). 24170767
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER2 Vaccine Phase II Actionable In Phase II clinical trials, ERBB2 (HER2) vaccines demonstrated safety and some efficacy in the adjuvant setting in ERBB2 (HER2)-positive breast cancer patients (PMID: 23585514). 23585514
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER2 Inhibitor Capecitabine + Tucatinib Phase Ib/II Actionable In a Phase Ib trial, the combination of Tucatinib (ARRY-380) with other agents demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 1/1 evaluable patient treated with Tucatinib (ARRY-380) and Capecitabine achieving CNS partial response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19). detail...
ERBB2 positive Advanced Solid Tumor predicted - sensitive ZW25 Phase I Actionable In a Phase I trial, ZW25 treatment resulted in partial response in 14% (2/14) and stable disease in 21% (3/14) of patients with ERBB2 (HER2)-positive tumors, including breast, gastric, esophageal, colorectal, and adnexal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive HER2 Inhibitor Neratinib + Paclitaxel Phase II Actionable In a Phase II trial, Nerlynx (neratinib) plus Taxol (paclitaxel) demonstrated similar efficacy to Herceptin (trastuzumab) plus Taxol (paclitaxel), with an median progression-free survival of 12.9 months, however, potentially decreased CNS metastasis risk, with an incidence of 8.3% (20/242) compared to 17.3% (41/237) in the Herceptin (trastuzumab) plus Taxol (paclitaxel) group (PMID: 27078022). 27078022
ERBB2 positive colorectal cancer no benefit ZW25 Phase I Actionable In a Phase I trial, ZW25 treatment resulted in disease progression in a patient with ERBB2 (HER2)-positive colorectal cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123). detail...
ERBB2 positive inflammatory breast carcinoma predicted - sensitive HER inhibitor (Pan) Afatinib Phase II Actionable In a Phase II clinical trial, treatment with Gilotrif (afatinib) resulted in a clinical benefit rate of 35% (9/26) in patients with ERBB2 (HER2)-positive inflammatory breast cancer, with 8 confirmed partial responses and 1 patient achieving stable disease for greater than 6 months (PMID: 27923043). 27923043
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER2 Inhibitor Ibrutinib Preclinical - Cell line xenograft Actionable In a preclinical study, Imbruvica (ibrutinib) inhibited Her family receptor signaling, resulted in apoptosis and growth inhibition in ERBB2 (HER2)-positive breast cancer cell lines in culture and in cell line xenograft models (PMID: 27256378). 27256378
ERBB2 positive ovarian cancer sensitive PRS-343 Preclinical - Cell line xenograft Actionable In a preclinical study, PRS-343 induced localized immune activation in cell line xenograft models of Erbb2 (Her2)-positive ovarian cancer, resulted in significant tumor growth inhibition (Eur J Cancer, Dec 2016, 69 (Suppl. 1): S99, abstract 301). detail...
ERBB2 positive ductal carcinoma in situ predicted - sensitive HER2-pulsed DC1 vaccine Phase Ib/II Actionable In a Phase I/Ib clinical trial, vaccination with a HER2-peptide pulsed dendritic cell vaccine was well-tolerated and resulted in immune response in patients with ERBB2 (HER2)-positive ductal carcinoma in situ (DCIS), and resulted in pathologic complete response rate of 28% (12/42), compared to 8.3% (1/12) in patients with invasive breast cancer (PMID: 27965306). 27965306
ERBB2 positive Her2-receptor positive breast cancer sensitive HER2 Inhibitor varlitinib Phase I Actionable In a Phase I expansion trial, 36% (5/14) of metastatic breast cancer patients positive for ERBB2 (HER2) demonstrated stable disease for up to 16 weeks when treated with Varlitinib (ARRY-334543) (Cancer Res May 1, 2009 69; 3603). detail...
ERBB2 positive gastroesophageal junction adenocarcinoma no benefit Paclitaxel + Trastuzumab + MM-111 Phase II Actionable In a Phase II trial, Taxol (paclitaxel) and Herceptin (trastuzumab) treatment in combination with MM-111 did not improve progression free survival (9.6 weeks) and median overall survival (32.1 weeks) compared to without MM-111 (23.3 weeks, 56.1 weeks) in ERBB2 positive gastroesophageal junction cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4043)). detail...
ERBB2 positive transitional cell carcinoma no benefit lapuleucel-T Phase II Actionable In a Phase II trial, Neuvenge (lapuleucel-T) treatment did not result in statistically significant improvement of overall survival (37.0 vs 22.2 months, HR = 0.96) or disease recurrence-free survival (11.9 vs 10.1 months, HR = 0.99) compared to standard of care in ERBB2 (HER2) positive urothelial cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4513)). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Pertuzumab + Trastuzumab + Paclitaxel Guideline Actionable Perjeta (pertuzumab), Herceptin (trastuzumab), and Taxol (paclitaxel) therapy is included in the guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-negative, ERBB2 (HER2) receptor-positive breast cancer (NCCN.org). detail...
ERBB2 positive ovarian cancer sensitive Hertuzumab-vc-MMAE Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive ovarian cancer cell lines in culture and inhibited tumor growth in ERBB2 (HER2)-positive ovarian cancer cell line xenograft models (PMID: 27509865). 27509865
ERBB2 positive Her2-receptor positive breast cancer sensitive CDX-3379 Preclinical Actionable In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-positive breast cancer (PMID: 26880266). 26880266
ERBB2 positive Her2-receptor positive breast cancer sensitive Lapatinib + Palbociclib Preclinical Actionable In a preclinical study, the combination of Tykerb (lapatinib) and Ibrance (palbociclib) worked additively to suppress growth of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 25221644). 25221644
ERBB2 positive breast cancer sensitive DS-8201a Preclinical - Pdx & cell culture Actionable In a preclinical study, DS-8201 inhibited growth of ERBB2 (HER2)-positive breast cancer cell lines in culture and xenograft models, and demonstrated antitumor activity in patient-derived xenograft (PDX) models of ERBB2 (HER2)-positive breast cancer, including models with low ERBB2 (HER2) expression (PMID: 27026201). 27026201
ERBB2 positive stomach cancer predicted - sensitive MGAH22 Phase I Actionable In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295). 28119295
ERBB2 positive stomach cancer predicted - sensitive MEDI4276 Phase I Actionable In a Phase I trial, MEDI4276 treatment resulted in complete response in 1 patient with breast cancer, partial response in 1 patient with breast cancer, and stable disease in 12 patients with Erbb2 (Her2)-positive breast or gastric cancer (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470; NCT02576548). detail...
ERBB2 positive glioblastoma multiforme sensitive HER2 CAR-T cells Phase I Actionable In a Phase I trial, glioblastoma patients positive for ERBB2 (HER2) demonstrated antitumor activity when treated with ERBB2 (HER2)-CAR-T cell therapy including one patient with a partial response and seven patients with stable disease ranging from 8 weeks to 29 months (PMID: 28426845). 28426845
ERBB2 positive Her2-receptor positive breast cancer sensitive HER2 BATs Preclinical - Cell culture Actionable In a preclinical study, HER2 BATs demonstrated enhanced toxicity comparing to unarmed T-cells against Erbb2 (Her2)-positive breast cancer cells in culture (PMID: 11359672). 11359672
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive ZW25 Phase I Actionable In a Phase I trial, ZW25 treatment resulted in partial response in 28.6% (2/7) and stable disease in 28.6% (2/7) of patients with ERBB2 (HER2)-positive breast cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123). detail...
ERBB2 positive Advanced Solid Tumor predicted - sensitive HER2 Inhibitor AC480 Phase I Actionable In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284). 21576284
ERBB2 positive Her2-receptor positive breast cancer sensitive Trodusquemine Preclinical - Cell line xenograft Actionable In a preclinical study, Trodusquemine (MSI-1436) inhibited tumor growth and metastasis in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model (PMID: 24845231). 24845231
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER inhibitor (Pan) Poziotinib Phase II Actionable In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in a median progression-free survival of 4.04 months, and a disease control rate of 75.49% (77/102; 20 partial responses) in heavily-treated Erbb2 (Her2)-positive breast cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 237O; NCT02418689). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab Guideline Actionable Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Oxaliplatin + Trastuzumab + TS-1 Phase II Actionable In a Phase II clinical trial, the combination of TS-1 (S-1) and Herceptin (trastuzumab) demonstrated safety and efficacy in patients with ERBB2 (HER2)-positive metastatic breast cancer, with an overall response rate of 53.6% (15/28), and a clinical benefit rate of 75.0% (21/28) (PMID: 24982373). 24982373
ERBB2 positive breast cancer sensitive XMT-1522 Preclinical - Pdx & cell culture Actionable In a preclinical study, XMT-1522 inhibited growth of Erbb2 (Her2)-positive breast cancer cells in culter, resulted in tumor regression in both cell line and patient-derived xenograft models (Cancer Res 2016;76(4 Suppl): Abstract nr P4-14-28). detail...
ERBB2 positive ovarian cancer sensitive ARX-788 Preclinical - Cell line xenograft Actionable In a preclinical study, an ERBB2 (HER2)-positive ovarian cancer xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639). detail...
ERBB2 positive sarcoma predicted - sensitive HER2 CAR-T cells Phase Ib/II Actionable In a Phase I/II trial, treatment with ERBB2 (HER2)-specific CAR-T cells resulted in stable disease for 12 weeks to 14 months in 4/17 evaluable patients with ERBB2 (HER2)-positive sarcomas and a median overall survival of 10.3 months (PMID: 25800760; NCT00902044). 25800760
ERBB2 positive Her2-receptor positive breast cancer sensitive HER2 Inhibitor Capecitabine + Neratinib Phase II Actionable In a Phase II trial, Nerlynx (neratinib) and Xeloda (capecitabine) combination therapy resulted in an overall 12-month survival rate of 63% (23/37) in patients with Erbb2 (Her2)-positive breast cancer brain metastases (J Clin Oncol 35, 2017 (suppl; abstr 1005)). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Everolimus + Vinorelbine Phase III Actionable In a Phase III trial (BOLERO-3), the combination of Afinitor (everolimus), Herceptin (trastuzumab), and Navelbine (vinorelbine) increased progression-free survival in patients with Herceptin (trastuzumab)-resistant, ERBB2 (HER2)-positive, advanced breast cancer who had prior taxane treatment (PMID: 24742739; NCT01007942). 24742739
ERBB2 positive Her2-receptor positive breast cancer sensitive Capecitabine + Trastuzumab Phase II Actionable In Phase II clinical trials, the combination of Xeloda (capecitabine) and Herceptin (trastuzumab) demonstrated efficacy with a manageable toxicity profile in heavily pretreated patients with ERBB2 (HER2)-positive advanced breast cancer and earlier Herceptin (trastuzumab) exposure (PMID: 17679724). 17679724
ERBB2 positive gastric adenosquamous carcinoma no benefit trastuzumab emtansine Phase III Actionable In a Phase III trial, Kadcyla (trastuzumab emtansine) did not demonstrated efficacy benefit over Taxol (paclitaxel) on median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl 4S; abstr 5)). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive MEDI4276 Phase I Actionable In a Phase I trial, MEDI4276 treatment resulted in complete response in 1 patient with breast cancer, partial response in 1 patient with breast cancer, and stable disease in 12 patients with Erbb2 (Her2)-positive breast or gastric cancer (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470; NCT02576548). detail...
ERBB2 positive Advanced Solid Tumor predicted - sensitive DS-8201a Phase I Actionable In a Phase I trial, treatment with DS-8201a was well-tolerated and resulted in an overall response rate (ORR) of 38% (19/50) and disease control rate (DCR) of 90% (45/50) in patients with ERBB2 (HER2)-expressing solid tumors, and an ORR of 29% (4/14) and DCR of 93% (13/14) in patients with low ERBB2 (HER2) expression (J Clin Oncol 35, 2017 (suppl; abstr 108)). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive CT-P6 Phase III Actionable In a Phase III trial, CT-P6 demonstrated equivalence to reference Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive breast cancer, with 46.8% (116/248) of patients treated with CT-P6 achieving pathologic complete response compared to 50.4% (129/256) with Herceptin (trastuzumab) treatment (PMID: 28592386). 28592386
ERBB2 positive esophageal cancer predicted - sensitive ZW25 Phase I Actionable In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123). detail...
ERBB2 positive stomach cancer sensitive ARX-788 Preclinical - Cell line xenograft Actionable In a preclinical study, ERBB2 (HER2)-positive ovarian xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639). detail...
ERBB2 positive gastroesophageal junction adenocarcinoma no benefit trastuzumab emtansine Phase III Actionable In a Phase III trial, Kadcyla (trastuzumab emtansine) did not demonstrated efficacy benefit over Taxol (paclitaxel) on median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl 4S; abstr 5)). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Pertuzumab + Trastuzumab + Docetaxel FDA approved Actionable In a Phase III trial (CLEOPATRA) that supported FDA approval, treatment with Perjeta (pertuzumab), combined with Herceptin (trastuzumab) and Taxotere (docetaxel), improved median progression free survival to 18.5 months compared to 12.4 months with placebo plus Herceptin (trastuzumab) and Taxotere (docetaxel) in patients with ERBB2 (HER2)-positive metastatic breast cancer (PMID: 23801166). 23801166
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER2 Inhibitor Capecitabine + Trastuzumab + Tucatinib Phase Ib/II Actionable In a Phase Ib trial, the combination of Tucatinib (ARRY-380), Herceptin (trastuzumab), and Capecitabine demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 50% (1/2) of evaluable patients achieving CNS partial response and 50% (1/2) achieving CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Oxaliplatin Preclinical Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive breast cancer cells in culture (PMID: 24300914). 24300914
ERBB2 positive breast cancer predicted - sensitive SYD985 Phase I Actionable In a Phase I trial, SYD985 treatment resulted in an overall response of 33% (33/99) and a median progression-free survival of 9.4 months in patients with ERBB2 (HER2)-positive (50) or ERBB2 (HER2)-low (49) metastatic breast cancer (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 1014-1014; NCT02277717). detail...
ERBB2 positive ovarian carcinoma sensitive SYD985 Preclinical - Cell culture Actionable In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive ovarian carcinoma cell line in culture (PMID: 25589493). 25589493
ERBB2 positive Her2-receptor positive breast cancer sensitive Lapatinib + MK2206 Phase I Actionable In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 6 months in 40% (2/5) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 27026198). 27026198
ERBB2 positive stomach cancer sensitive MI130004 Preclinical - Cell line xenograft Actionable In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-positive gastric cancer cells in culture, and led to decreased tumor volume and improved survival in cell line xenograft models (PMID: 29440297). 29440297
ERBB2 positive stomach carcinoma sensitive HER2 Inhibitor Tucatinib Preclinical - Cell culture Actionable In a preclinical study, Tucatinib (ARRY-380) inhibited tumor growth in a ERBB2 (HER2)-positive gastric carcinoma cell line xenograft model (Cancer Res April 15, 2012 72:852). detail...
ERBB2 positive breast cancer sensitive Withacnistin Preclinical Actionable In a preclinical study, withacnistin induced tumor regression in transgenic mouse models of Erbb2 (Her2)-driven breast cancer (PMID: 24983364). 24983364
ERBB2 positive colorectal cancer predicted - sensitive DS-8201a Phase I Actionable In a Phase I trial, treatment with DS-8201a resulted in an objective response rate of 25% (3/12) and disease control rate of 83.3% (10/12) in evaluable patients with Erbbe (Her2)-expressing colorectal cancer (Annals of Oncology (2018) 29 (suppl_8): viii150-viii204; NCT02564900). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Docetaxel + T-DM1 + Pertuzumab Phase Ib/II Actionable In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine), Taxotere (docetaxel) and Perjeta (pertuzumab) combination treatment resulted in pathologic complete response in 60.3% (44/73) of patients with ERBB2 (HER2)-positive locally advanced breast cancer (PMID: 27052654). 27052654
ERBB2 positive Her2-receptor positive breast cancer sensitive HER2 Inhibitor Tucatinib Phase I Actionable In a Phase I trial, treatment with Tucatinib (ARRY-380) resulted in a response rate of 14% (3/22; all partial responses (PR)) and a clinical benefit rate (PR plus stable disease for greater than or equal to 24 weeks) of 27% (6/22) in Erbb2 (Her2)-positive breast cancer patients (PMID: 28053022). 28053022
ERBB2 positive Her2-receptor positive breast cancer sensitive HER inhibitor (Pan) Afatinib + Trastuzumab Phase I Actionable In a Phase I clinical trial, ERBB2 (HER2)-positive breast cancer patients treated with Gilotrif (afatinib), in combination with Herceptin (trastuzumab), demonstrated an overall objective response rate of 11% (2/18) while 28% (5/18) attained a best response of stable disease (PMID: 25370464). 25370464
ERBB2 positive ovarian cancer sensitive MI130004 Preclinical - Cell line xenograft Actionable In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-positive ovarian cancer cells in culture, and led to decreased tumor volume, reduced ERBB2 (HER2) expression, and improved survival in cell line xenograft models (PMID: 29440297). 29440297
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER2 Inhibitor Trastuzumab + Tucatinib Phase Ib/II Actionable In a Phase Ib clinical trial, the combination of Tucatinib (ARRY-380) and Herceptin (trastuzumab) demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 100% (3/3) patients achieving CNS stable disease as best response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19). detail...
ERBB2 positive breast cancer sensitive ARX-788 Preclinical - Cell line xenograft Actionable In a preclinical study, an ERBB2 (HER2)-positive breast cancer xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Metformin Phase III Actionable In a Phase III trial, ERBB2 (HER2) positive breast cancer patients with diabetes demonstrated a greater disease free survival and overall survival when treated with Glucophage (metformin) compared to ERBB2 (HER2) positive breast cancer patients with diabetes not treated with Glucophage (metformin) (PMID: 28375706). 28375706
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER2 Inhibitor Tucatinib + Trastuzumab emtansine Phase Ib/II Actionable In a Phase Ib trial, the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 12.5% (1/8) evaluable patients achieving CNS complete response, 25% (2/8) partial CNS response, and 62.5% (5/8) CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER2 Inhibitor Tucatinib + Trastuzumab emtansine Phase Ib/II Actionable In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in an overall response rate of 47% (15/52) and median progression-free survival of 6.5 months in patients with ERBB2 (HER2)-positive metastatic breast cancer, including patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 513)). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER2 Inhibitor Tucatinib + Trastuzumab emtansine Phase Ib/II Actionable In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in partial response in 33% (11/33) and stable disease in 48% (16/33) and a clinical benefit rate of 58% (19/33) in patients with ERBB2 (HER2)-positive metastatic breast cancer (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-20). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive SB3 Phase III Actionable In a Phase III trial, SB3 treatment demonstrated safety, immunogenicity, and survival result similar to Herceptin (trastuzumab), resulted in event-free-survival rates of 92.2% and 91.6%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 153PD; NCT02149524). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide Guideline Actionable Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org). detail...
ERBB2 positive stomach cancer sensitive DS-8201a Preclinical - Pdx & cell culture Actionable In a preclinical study, DS-8201 inhibited growth of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture and in xenograft models, and induced tumor regression in a patient-derived xenograft (PDX) model of ERBB2 (HER2)-positive gastric cancer (PMID: 27026201). 27026201
ERBB2 positive Her2-receptor positive breast cancer sensitive Pertuzumab + Trastuzumab Phase III Actionable In a Phase III trial, adjuvant Herceptin (trastuzumab), Perjeta (pertuzumab), plus chemotherapy resulted in improved invasive disease-free survival compared to Herceptin (trastuzumab) plus chemotherapy in patients with Erbb2 (Her2)-positive breast cancer (J Clin Oncol 35, 2017 (suppl; abstr LBA500)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02658084 Phase Ib/II Trastuzumab emtansine + Vinorelbine Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer Terminated
NCT02213744 Phase II Vinorelbine + Trastuzumab Capecitabine + Trastuzumab Gemcitabine + Trastuzumab MM-302 + Trastuzumab MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients Terminated
NCT02132949 Phase II Pertuzumab + Trastuzumab Paclitaxel + Doxorubicin + Cyclophosphamide Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer. Active, not recruiting
NCT01434303 Phase I Entinostat + Lapatinib + Trastuzumab Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only Active, not recruiting
NCT02025192 Phase I Trastuzumab + Tucatinib Capecitabine + Tucatinib A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Active, not recruiting
NCT02345772 Phase I Fulvestrant Pertuzumab + Trastuzumab + Docetaxel Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer Terminated
NCT03662659 Phase II Nivolumab + Relatlimab + TS-1 FOLFOX + Nivolumab + Relatlimab Nivolumab + TS-1 Capecitabine + Nivolumab + Oxaliplatin Nivolumab + mFOLFOX-6 Capecitabine + Nivolumab + Oxaliplatin + Relatlimab An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers Recruiting
NCT03329378 Phase II Docetaxel + Paclitaxel + Pegfilgrastim + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer Recruiting
NCT03342417 Phase II Nivolumab + Ipilimumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Recruiting
NCT02598427 Phase I Pertuzumab + Trastuzumab Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer Terminated
NCT02236000 Phase Ib/II Neratinib + trastuzumab emtansine A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer Recruiting
NCT02414646 Phase II Trastuzumab Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer Active, not recruiting
NCT02340221 Phase III Fulvestrant Taselisib SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy Active, not recruiting
NCT01494662 Phase II Capecitabine + Neratinib Neratinib HKI-272 for HER2-Positive Breast Cancer and Brain Metastases Recruiting
NCT02335411 Phase II Pembrolizumab Cisplatin + Fluorouracil A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) Active, not recruiting
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated
NCT03088527 Phase I RAD140 A Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Recruiting
NCT02774681 Phase II Palbociclib + Trastuzumab Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis Active, not recruiting
NCT01989676 Phase III Trastuzumab + Paclitaxel A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) Active, not recruiting
NCT03500991 Phase I HER2 CAR-T cells HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Recruiting
NCT02827877 Phase I Pertuzumab + Trastuzumab Copper (Cu) 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer Recruiting
NCT02751528 ETBX-021 QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer Recruiting
NCT02492711 Phase III Vinorelbine Capecitabine Gemcitabine Trastuzumab Eribulin MGAH22 Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Recruiting
NCT02649686 Phase I MEDI4736 + Trastuzumab Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab Active, not recruiting
NCT03366844 Phase I Pembrolizumab Pilot; Open Label; Breast Cancer; Preoperative Pembrolizumab + Radiation Recruiting
NCT01702571 Phase III trastuzumab emtansine A Study of Kadcyla (Trastuzumab Emtansine) in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment Active, not recruiting
NCT01853748 Phase II Trastuzumab + Paclitaxel trastuzumab emtansine T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Active, not recruiting
NCT02073487 Phase II Paclitaxel Trastuzumab emtansine + Lapatinib Trastuzumab + Lapatinib nab-paclitaxel Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel Active, not recruiting
NCT01966471 Phase III T-DM1 + Pertuzumab Pertuzumab + Trastuzumab + Docetaxel Pertuzumab + Trastuzumab + Paclitaxel A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer Active, not recruiting
NCT03747120 Phase II Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab Paclitaxel + Pembrolizumab + Trastuzumab Pertuzumab + Trastuzumab + Paclitaxel Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab Recruiting
NCT03389230 Phase I HER2 CAR-T cells Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Recruiting
NCT03742245 Phase I Olaparib + Vorinostat Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer Not yet recruiting
NCT03529110 Phase III DS-8201a trastuzumab emtansine DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Recruiting
NCT02536339 Phase II Pertuzumab + Trastuzumab Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy Active, not recruiting
NCT03284723 Phase I PF-06804103 PF-06804103 Dose Escalation in HER2 Positive Solid Tumors Recruiting
NCT02224599 Phase Ib/II Autologous TAPA-pulsed dendritic cell vaccine + Cyclophosphamide Treatment of Patients With Progressive and/or Refractory Solid Malignancies Active, not recruiting
NCT01305941 Phase II Trastuzumab + Everolimus + Vinorelbine A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases Completed
NCT03448042 Phase I BTRC 4017A A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers Recruiting
NCT01855828 Phase II Pertuzumab + Trastuzumab + Paclitaxel Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer Active, not recruiting
NCT01921335 Phase I Trastuzumab + Tucatinib Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer Active, not recruiting
NCT01367002 Phase II Trastuzumab Paclitaxel + Carboplatin Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Active, not recruiting
NCT02274012 Phase II Afatinib + Paclitaxel Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer Withdrawn
NCT02154529 Phase Ib/II XL647 + Trastuzumab Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Terminated
NCT03321981 Phase II Letrozole + MCLA-128 Anastrozole + MCLA-128 Fulvestrant + MCLA-128 Exemestane + MCLA-128 MCLA-128 + Trastuzumab MCLA-128 + Trastuzumab + Vinorelbine MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer Recruiting
NCT03218826 Phase I AZD8186 + Docetaxel PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Recruiting
NCT01641939 Phase III Docetaxel Paclitaxel trastuzumab emtansine A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer Terminated
NCT01275677 Phase III Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide Docetaxel + Cyclophosphamide Docetaxel + Cyclophosphamide + Trastuzumab Paclitaxel + Doxorubicin + Cyclophosphamide Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Active, not recruiting
NCT02297230 Phase Ib/II Capecitabine Paclitaxel Trastuzumab + Paclitaxel Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics Terminated
NCT02650752 Phase I Lapatinib + Capecitabine Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases Active, not recruiting
NCT03624543 Phase II CFI-400945 CFI-400945 in Patients With Advanced/Metastatic Breast Cancer Recruiting
NCT02605915 Phase I Atezolizumab + Trastuzumab Docetaxel Carboplatin Pertuzumab Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer Active, not recruiting
NCT02659514 Phase II Poziotinib Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer Active, not recruiting
NCT03054363 Phase Ib/II Letrozole + Palbociclib + Tucatinib Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer Recruiting
NCT01848756 Phase Ib/II SNX-5422 Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Terminated
NCT03615326 Phase III Oxaliplatin + Trastuzumab + TS-1 Capecitabine + Oxaliplatin + Trastuzumab Oxaliplatin + Pembrolizumab + Trastuzumab + TS-1 Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Recruiting
NCT02390427 Phase I Trastuzumab Paclitaxel Pertuzumab Taselisib Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer Recruiting
NCT02000622 Phase III Olaparib Vinorelbine Eribulin Capecitabine Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. Active, not recruiting
NCT02947685 Phase III Fulvestrant Pertuzumab Letrozole Anastrozole Exemestane Trastuzumab Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) Recruiting
NCT01702558 Phase II trastuzumab emtansine trastuzumab emtansine + Capecitabine A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer Completed
NCT03032107 Phase I Pembrolizumab + trastuzumab emtansine A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 Recruiting
NCT01697293 Phase Ib/II Paclitaxel + Triciribine Doxorubicin + Cyclophosphamide Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Recruiting
NCT01816035 Phase I trastuzumab emtansine Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery Completed
NCT02673398 Phase II Neratinib Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer Recruiting
NCT03709082 Phase Ib/II Ado-trastuzumab emtansine + Letrozole + Palbociclib Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Recruiting
NCT02442297 Phase I HER2 sensitized T-cells T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma Recruiting
NCT02314117 Phase III Capecitabine Fluorouracil Cisplatin Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Active, not recruiting
NCT01283789 Phase II Everolimus + Lapatinib Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer Unknown status
NCT02500199 Phase I Pyrotinib Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy Recruiting
NCT02252887 Phase II Gemcitabine + Trastuzumab + Pertuzumab Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab-Based Therapy, TDM-1, and TDM-1 + Pertuzumab Active, not recruiting
NCT01920061 Phase I PF-05212384 + Dacomitinib PF-05212384 + Cisplatin Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents Recruiting
NCT01118975 GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers Terminated
NCT02139358 Phase Ib/II Gemcitabine + Trastuzumab + Pertuzumab Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Active, not recruiting
NCT02167854 Phase I BYL719 + LJM716 + Trastuzumab Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer Active, not recruiting
NCT00796978 Phase II Trastuzumab Trastuzumab in Treating Older Women With Early-Stage Breast Cancer Active, not recruiting
NCT02234596 Phase II Nintedanib Nintedanib in Patients With Advanced Esophagogastric Cancer Active, not recruiting
NCT01774851 Phase II Paclitaxel + Trastuzumab + MM-111 Trastuzumab + Paclitaxel A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Terminated
NCT03694522 Phase III FPA144 + Fluorouracil + Leucovorin + Oxaliplatin mFOLFOX-6 A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT) Recruiting
NCT02657343 Phase Ib/II Ribociclib Trastuzumab trastuzumab emtansine An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Recruiting
NCT01491737 Phase II Anastrozole Letrozole Trastuzumab Pertuzumab + Trastuzumab A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer Active, not recruiting
NCT02593708 Phase I Neratinib + Paclitaxel + Pertuzumab + Trastuzumab Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ Terminated
NCT03199885 Phase III Pertuzumab + Trastuzumab + Paclitaxel Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer Not yet recruiting
NCT03255070 Phase I ARX-788 A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression Recruiting
NCT02675231 Phase II Abemaciclib Trastuzumab Fulvestrant A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer Active, not recruiting
NCT02402712 Phase III Pertuzumab + Trastuzumab + Docetaxel Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer Active, not recruiting
NCT02654119 Phase II Cyclophosphamide + Paclitaxel + Trastuzumab Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery Recruiting
NCT02569801 Phase II GDC-0810 Fulvestrant A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy Active, not recruiting
NCT01873833 Phase II Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer Active, not recruiting
NCT03368729 Phase Ib/II Niraparib + Trastuzumab Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Not yet recruiting
NCT02040857 Phase II Exemestane Palbociclib Tamoxifen Letrozole Anastrozole Palbociclib + Endocrine Therapy for HR + BrCa Active, not recruiting
NCT03680560 Phase I ACTR707 + Trastuzumab ACTR087 + Trastuzumab Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers Recruiting
NCT03289039 Neratinib Fulvestrant + Neratinib A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer Recruiting
NCT02411656 Phase II Pembrolizumab MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC) Recruiting
NCT01570036 Phase II E75 Sargramostim Trastuzumab Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Completed
NCT00574587 Phase Ib/II vorinostat + Paclitaxel Trastuzumab Doxorubicin + Cyclophosphamide Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis Unknown status
NCT01937117 Phase II Pertuzumab + Trastuzumab Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Completed
NCT02229149 Phase II Paclitaxel Docetaxel Pertuzumab + Trastuzumab nab-paclitaxel Vinorelbine Trastuzumab Capecitabine Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer Active, not recruiting
NCT02066532 Phase Ib/II Ruxolitinib + Trastuzumab Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Recruiting
NCT01875666 Phase I Trastuzumab + Lapatinib Trastuzumab Pertuzumab Pertuzumab + Trastuzumab Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib Active, not recruiting
NCT03384940 Phase II DS-8201a DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer Recruiting
NCT02571530 Phase I Trastuzumab Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer Recruiting
NCT01273610 Phase II Trastuzumab + Lapatinib Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer Active, not recruiting
NCT01384253 Phase I 212Pb-TCMC-Trastuzumab + Trastuzumab Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Completed
NCT02564900 Phase I DS-8201a Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors Active, not recruiting
NCT03568422 Phase Ib/II CFI-402257 + Paclitaxel CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer Recruiting
NCT03493854 Phase III Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Active, not recruiting
NCT01828021 Phase II MGAH22 Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer Completed
NCT03179904 Phase II Paclitaxel + Trastuzumab + TVB-2640 FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer Recruiting
NCT01904903 Phase II Pertuzumab trastuzumab emtansine Trastuzumab Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt) Active, not recruiting
NCT03248492 Phase II DS-8201a DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Active, not recruiting
NCT01924351 Phase II HER2-positive Breast Cancer With Brain Metastasis (GCC 1345) Withdrawn
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Active, not recruiting
NCT02115282 Phase III Goserelin Entinostat Exemestane Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Active, not recruiting
NCT01300962 Phase I BKM120 + Capecitabine + Lapatinib BKM120 + Capecitabine + Trastuzumab BKM120 + Capecitabine BYL719 + Capecitabine Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer Active, not recruiting
NCT01983501 Phase I Tucatinib + Trastuzumab emtansine A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer Active, not recruiting
NCT03777657 Phase III Capecitabine + Oxaliplatin Cisplatin + Fluorouracil BGB-A317 + Capecitabine + Oxaliplatin BGB-A317 + Cisplatin + Fluorouracil Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Recruiting
NCT01358877 Phase III Pertuzumab Trastuzumab A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer Active, not recruiting
NCT01565083 Phase II Pertuzumab + Trastuzumab + Vinorelbine A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer Completed
NCT03238495 Phase II Pertuzumab + Trastuzumab + Carboplatin + Docetaxel Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer Recruiting
NCT02386501 ADXS31-164 Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors Active, not recruiting
NCT01276041 Phase II Pertuzumab + Trastuzumab + Paclitaxel Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer Active, not recruiting
NCT03433313 Phase III Cyclophosphamide + Epirubicin + Paclitaxel + Trastuzumab Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer Recruiting
NCT01513083 Phase I trastuzumab emtansine A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function Completed
NCT01196390 Phase III Paclitaxel + Carboplatin + Trastuzumab Paclitaxel + Carboplatin Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting
NCT02063724 Phase I HER2-pulsed DC1 vaccine HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant) Active, not recruiting
NCT03602079 Phase Ib/II A166 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting
NCT02000596 Phase II Pertuzumab + Trastuzumab Anastrozole + Fulvestrant Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC Terminated
NCT02206984 Phase I Tamoxifen Anastrozole Fulvestrant Endocrine Response in Women With Invasive Lobular Breast Cancer Recruiting
NCT03304080 Phase Ib/II Anastrozole + Palbociclib + Pertuzumab + Trastuzumab Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast Recruiting
NCT01572038 Phase III Pertuzumab + Trastuzumab nab-paclitaxel Docetaxel Paclitaxel A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE) Active, not recruiting
NCT01922921 Phase Ib/II HER-2/neu intracellular domain protein + Trastuzumab HER-2/neu intracellular domain protein + Trastuzumab + Polysaccharide-K Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Active, not recruiting
NCT01016886 Phase Ib/II Bisoprolol Perindopril Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Unknown status
NCT01796197 Phase II Doxorubicin + Cyclophosphamide Pertuzumab + Trastuzumab Paclitaxel Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa Active, not recruiting
NCT01772472 Phase III trastuzumab emtansine Trastuzumab A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Active, not recruiting
NCT00902044 Phase I Fludarabine Cyclophosphamide HER2 sensitized T-cells Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma Recruiting
NCT02326974 Phase II T-DM1 + Pertuzumab T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA Active, not recruiting
NCT03716180 Phase I Pertuzumab + Trastuzumab + Paclitaxel DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC Recruiting
NCT02491099 Phase II Afatinib A Phase II Evaluation of Afatinib Recruiting
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab Cetuximab + CDX-3379 CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed
NCT03523572 Phase I DS-8201a + Nivolumab Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer Recruiting
NCT02318901 Phase Ib/II Pembrolizumab + trastuzumab emtansine Pembrolizumab + Trastuzumab Pembrolizumab + Cetuximab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated
NCT03521245 Phase I Trastuzumab Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer Recruiting
NCT03330561 Phase I PRS-343 PRS-343 in HER2-Positive Solid Tumors Recruiting
NCT02038010 Phase I BYL719 + Trastuzumab emtansine BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx Active, not recruiting
NCT02689921 Phase II Anastrozole Letrozole Leuprolide Pertuzumab + Trastuzumab Exemestane NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT) Active, not recruiting
NCT01522768 Phase II Afatinib + Trastuzumab Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer Recruiting
NCT02689284 Phase Ib/II MGAH22 + Pembrolizumab Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer Recruiting
NCT03125200 Phase I ADCT-502 Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression Terminated
NCT03530696 Phase II trastuzumab emtansine PD-0332991 + T-DM1 T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1) Recruiting
NCT03112590 Phase Ib/II Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer Recruiting
NCT01191697 Phase II Trastuzumab + Bevacizumab Capecitabine + Oxaliplatin CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer Active, not recruiting
NCT02545504 Phase III Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab GS-5745 GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Active, not recruiting
NCT01934894 Phase II Cabazitaxel + Lapatinib Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases Terminated
NCT02297698 Phase II Sargramostim Trastuzumab E75 Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients Active, not recruiting
NCT02061332 Phase Ib/II HER2-pulsed DC1 vaccine DC Vaccine for Patients With Ductal Carcinoma In Situ Active, not recruiting
NCT02614794 Phase II Capecitabine + Trastuzumab + Tucatinib Capecitabine + Trastuzumab Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer Recruiting
NCT02003209 Phase III Goserelin Pertuzumab + Trastuzumab + Carboplatin + Docetaxel Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Active, not recruiting
NCT02091960 Phase II Enzalutamide + Trastuzumab A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer Active, not recruiting
NCT02403271 Phase Ib/II Ibrutinib + MEDI4736 A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors Completed
NCT01226316 Phase I Capivasertib Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Active, not recruiting
NCT02789657 Phase II Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel Doxorubicin + Cyclophosphamide BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. Recruiting
NCT01160211 Phase III Trastuzumab + Lapatinib Letrozole Anastrozole Lapatinib Trastuzumab Exemestane A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Active, not recruiting
NCT02289833 Phase II trastuzumab emtansine A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed
NCT02924883 Phase II Trastuzumab Atezolizumab + Trastuzumab A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy Active, not recruiting
NCT01602406 Phase I LJM716 + Trastuzumab Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer Completed
NCT03650348 Phase I Atezolizumab + PRS-343 PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors Recruiting
NCT01976169 Phase I PD-0332991 + T-DM1 Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) Recruiting
NCT02131064 Phase III T-DM1 + Pertuzumab Pertuzumab + Trastuzumab + Carboplatin + Docetaxel A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer Completed
NCT02060253 Phase I Ganetespib + Paclitaxel + Trastuzumab Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer Completed
NCT01774786 Phase III Pertuzumab Capecitabine + Fluorouracil + Cisplatin + Trastuzumab A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Active, not recruiting
NCT01912963 Phase II Eribulin Pertuzumab Trastuzumab Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer Terminated
NCT00889954 Phase I Autologous TGF beta resistant HER2 EBV CTLs Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy Completed
NCT01325207 Phase Ib/II Trastuzumab Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer Active, not recruiting
NCT03190967 Phase Ib/II trastuzumab emtansine Temozolomide + Trastuzumab emtansine T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery Recruiting
NCT02892123 Phase I ZW25 Trial of ZW25 in Patients With Advanced HER2-expressing Cancers Recruiting
NCT02152943 Phase I Everolimus + Letrozole + Trastuzumab Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Recruiting
NCT01008150 Phase II Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer Completed
NCT01808573 Phase III Lapatinib + Capecitabine Capecitabine + Neratinib A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting Active, not recruiting
NCT01566721 Phase III Trastuzumab A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer) Active, not recruiting
NCT01148849 Phase I MGAH22 Safety Study of MGAH22 in HER2-positive Carcinomas Active, not recruiting
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Recruiting
NCT03523585 Phase III DS-8201a Lapatinib + Capecitabine Capecitabine + Trastuzumab DS-8201a Versus Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care Recruiting
NCT03451162 Phase I DHES0815A Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer Recruiting
NCT02965885 Phase I TAS-116 A Study of TAS-116 in Patients With Solid Tumors Active, not recruiting
NCT01901146 Phase III Epirubicin + Cyclophosphamide Trastuzumab + Paclitaxel Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac) Completed
NCT02336984 Phase Ib/II Trastuzumab HER2-pulsed DC1 vaccine A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS Active, not recruiting
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Recruiting
NCT01783756 Phase Ib/II Lapatinib + Capecitabine + Everolimus Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis Active, not recruiting
NCT01450696 Phase III Capecitabine + Cisplatin + Trastuzumab HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer Terminated